Citations

Clear

3042 citation(s) found for "Kumar, S".

Outcomes of Underwater Endoscopic Mucosal Resection for Giant Colorectal Polyps: A Multicenter Study
Karna, Rahul , Wilson, Natalie , Seid, Amir S, Larsen, Kaylee, Enke, Thomas , Hassam, Ali, Kumar, Anand R, Shah, Shawn L, Zhao, Joy, Choi, Alyssa Y, Issa, Danny, Saeed, Ahmed, Phan, Jennifer, Mosko, Jeffrey D, Dang, Frances, Westanmo, Anders, Reinink, Andrew, Samarasena, Jason B, Shaukat, Aasma, Mosko, Jeffrey D. , Bilal, Mohammad , Karna, Rahul , Larsen, Kaylee, Enke, Thomas , Choi, Alyssa Y. , Issa, Danny , Saeed, Ahmed, Phan, Jennifer, Dang, Frances , Westanmo, Anders , Reinink, Andrew R. , Samarasena, Jason , Shaukat, Aasma , Bilal, Mohammad , Wilson, Natalie

Mayo Clinic

Endoscopy International Open | July 15, 2026 | Volume: 14 | Issue: CP | Pages: No page available

10.1055/a-2910-5182 | PMID 42592233 Get It

Abstract Introduction Underwater endoscopic mucosal resection (uEMR) technique has gained popularity for removal of large non-pedunculated colorectal polyps (LNPCPs) due to high en-bloc resection rates and lower recurrence rates. However, there is no information regarding outcomes of uEMR for giant colorectal polyps. Therefore, we aimed to evaluate the outcomes of uEMR for giant colorectal polyps across multiple centers in North America. Methods We conducted a multicenter retrospective study of adults with giant colorectal polyps undergoing uEMR between January 2019 and November 2025. Giant colorectal polyps were defined as LNPCPs ≥40 mm. Primary outcomes were technical success and rate of recurrent adenoma. Secondary outcomes were severe adverse events (SAEs) and predictors of technical success, recurrence, and SAEs. Results A total of 137 polyps, with mean polyp size 47.6 mm were included. Majority of the lesions were located in right colon (61%, n = 83) with the most common histopathology being high-grade dysplasia (HGD) (31.4%, n = 43). Technical success was achieved in 90.5% (n = 124) with en-bloc resection rate of 11.7% (n = 16). Polyp fibrosis (OR: 0.08) and HGD (OR: 0.15) were independent predictors of inability to achieve technical success. Of 92 (67.1%) patients with follow-up, recurrent polyp was present in 8.7% (n = 8). SAEs were noted in 9.5%, consisting of delayed bleeding (9.5%, n = 13), while no delayed perforation or post polypectomy syndrome was noted. Discussion Our study demonstrates that uEMR is technically feasible for the removal of giant colorectal polyps with an acceptable safety profile and recurrence rate.
Modifiable Risk Factors and Attributable Ischemic Heart Disease Mortality in US States, 1990-2023
Benziger, Catherine P., Stark, Benjamin A., Johnson, Catherine O., Roth, Gregory A., Collaborators, GBD 2023 US IHD, Abohashem, Shady, Ahmed, Syed Anees, Al-Aly, Ziyad, Alsabri, Mohammed A., Antony, Catherine M., Aravkin, Aleksandr Y., Areda, Demelash, Bell, Michelle L., Brauer, Michael, Chi, Gerald, Criqui, Michael H., Dai, Xiaochen, Doshi, Ojas Prakashbhai, Doshi, Rajkumar Prakashbhai, E’mar, Abdel Rahman, Elhadi, Muhammed, Göbölös, Laszlo, Haile, Demewoz, Hebert, Jeffrey J., Hemmati, Mehdi, Ibrahim, Ramzi, Kankam, Samuel Berchi, Kantar, Rami S., Khubchandani, Jagdish, Kim, Min Seo, Kimokoti, Ruth W., Kisa, Adnan, Kokkorakis, Michail, Kumar, Ashish, Liu, Xuefeng, Lv, Lei, Mahmoudi, Morteza, Manla, Yosef, Martinez-Piedra, Ramon, Marzouk, Sammer, Mensah, George A., Mestrovic, Tomislav, Miller, Ted R., Mokdad, Ali H., Mougin, Vincent, Mustafa, Ahmad, Nassar, Mahmoud, Natto, Zuhair S., Nugen, Fred, Parikh, Romil R., Pasovic, Maja, Patil, Shankargouda, Puvvula, Jagadeesh, Ramasamy, Shakthi Kumaran, Rashid, Ahmed Mustafa, Root, Kevin T., Sawhney, Monika, Schuermans, Art, Shariff, Mariam, Shuval, Kerem, Simegn, Gizeaddis Lamesgin, Singh, Rohit, Stafford, Lauryn K., Taiba, Jabeen, Tanwar, Manoj, Teramoto, Masayuki, Thirunavukkarasu, Sathish, Tran, Thang Huu, Uppal, Dipan, Vinayak, Manish, Yuce, Deniz, Murray, Christopher J. L., Moran, Andrew E., Kimokoti, Ruth W , Liu, Xuefeng , Nassar, Mahmoud , Singh, Rohit , Tanwar, Manoj , Yu, Hairui , Taiba, Jabeen , Benziger, Catherine P. , Stark, Benjamin, Johnson, Catherine O., Roth, Gregory A. , Collaborators, GBD, Abohashem, Shady , Al‐Aly, Ziyad , Antony, Catherine M, Aravkin, Aleksandr Y. , Areda, Demelash, Bräuer, Michael , Chi, Gerald , Criqui, Michael H. , Doshi, Ojas Prakashbhai , Doshi, Rajkumar , E’mar, Abdel Rahman, Elhadi, Muhammed, Göbölös, László , Haile, Demewoz , Hébert, Jeffrey J. , Hemmati, Mehdi , Ibrahim, Ramzi , Kankam, Samuel Berchi , Kantar, Rami S. , Khubchandani, Jagdish , Kısa, Adnan , Kokkorakis, Michail , Lv, Lei , Mahmoudi, Morteza , Manla, Yosef , Martínez, Ramón , Marzouk, Sammer , Mensah, George A. , Meštrović, Tomislav , Miller, Ted R. , Mokdad, Ali H. , Mougin, Vincent , Mustafa, Ahmad , Nassar, Mahmoud, Nugen, Fred , Pasovic, Maja , Puvvula, Jagadeesh , Rashid, Ahmed Mustafa , Root, Kevin T., Sawhney, Monika, Schuermans, Art , Shariff, Mariam , Shuval, Kerem , Simegn, Gizeaddis Lamesgin , Stafford, Lauryn K , Teramoto, Masayuki , Thirunavukkarasu, Sathish, Uppal, Dipan , Vinayak, Manish , Yuce, Deniz, Murray, Christopher J. L., Moran, Andrew Edward

Mayo Clinic

JAMA Cardiology | July 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamacardio.2026.2435 | PMID 42455550 Get It

Importance Ischemic heart disease (IHD), the leading cause of death in the US, is predominantly due to modifiable risk factors. Estimates of IHD mortality attributable to risk factors provide evidence for health policy decision-making. Objective To estimate the burden of IHD death attributable to risk factors in the US from 1990-2023. Design, Setting, and Participants The Global Burden of Disease Study 2023 (GBD 2023) used vital records and a broad set of epidemiologic data to estimate IHD death rates, risk factor exposure, and relative risk curves for risk-outcome pairs for 1990-2023 for the general population. Data analysis was performed from October 2024 to December 2025. Exposure Twelve metabolic, behavioral, and environmental risk factors. Main Outcomes and Measures The primary outcomes were IHD death rates per 100 000 persons, counts, and attributable risks from 1990-2023 by age, sex, and US state. Estimates include 95% uncertainty intervals (UI). IHD death rates were estimated using ensemble modeling methods. Risk exposures were estimated using bayesian meta-regression methods. Relative risks were estimated following the Burden of Proof framework. Results In 2023, there were 473 000 IHD deaths (95% UI, 414 000-510 000) in the US, a decrease of 58.7% (95% UI, 56.8%-61.0%) in age-standardized rate since 1990. Between 2010 and 2023, there was a 19.0% decrease (95% UI, 15.0%-22.9%) for males and a 24.5% decrease (95% UI, 20.3%-29.7%) for females in IHD death rates. High systolic blood pressure (SBP), dietary risks, and high low-density lipoprotein cholesterol (LDL-C) were the leading risk factors for IHD deaths in 2023, accounting for 47.2% (95% UI, 36.4%-57.0%), 38.6% (95% UI, 17.2%-56.8%), and 28.5% (95% UI, 19.3%-39.6%) of IHD deaths, respectively. Increased exposure to several risk factors substantially increased their attributable burden for IHD deaths in 2023, with high fasting plasma glucose (FPG) increasing 38.8% (95% UI, 11.5%-81.1%) and high body mass index (BMI) increasing 54.5% (95% UI, 41.8%-66.3%) since 1990. Smoking and particulate matter pollution had the greatest decrease in attributable IHD mortality since 1990, at 33.3% (95% UI, 23.6%-41.7%) and 74.9% (95% UI, 46.7%-88.8%), respectively. Conclusion and Relevance Per the results of this systematic analysis of GBD 2023, a total of 88.7% (95% UI, 83.4%-92.5%) of IHD deaths were attributable to modifiable risk factors in the US in 2023, with high SBP, dietary risks, and high LDL-C being the greatest contributors. High BMI and high FPG showed the largest attribution increases, while exposure to other risks did not increase significantly for the population.
Potential of new BCMA-targeting therapies in overcoming resistance in multiple myeloma
Kumar, Shaji, Sra, Manraj Singh , Singh, Manraj

Mayo Clinic

Expert Opinion on Biological Therapy | July 11, 2026 | Volume: 26 | Issue: 7 | Pages: 665-676

10.1080/14712598.2026.2703858 | PMID 42434875 Get It

Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology
Gradishar, W J, Moran, Meena S. , Abraham, Jame , Abramson, Vandana, Aft, Rebecca, Agnese, Doreen, Allison, Kimberly H., Anderson, Bethany, Bailey, Janet, Burstein, Harold J. , Chen, Nan , Chew, Helen, Dang, Chau, Giordano, Sharon H., Goetz, Matthew P., Jankowitz, Rachel C., Javid, Sara H., Leitch, A. Marilyn, LYONS, JANICE, McCloskey, Susie, McShane, Melissa , Patel, Sameer A. , Rosenberger, Laura H., Santa‐Maria, Cesar A. , Schneider, Bryan P., Smith, Mary Lou , Soliman, Hatem, Speers, Corey, Telli, Melinda L. , Wei, Mei , Wisinski, Kari B., Yellala, Amulya, Schonfeld, Ryan, Telli, Melinda L , Gradishar, William John, Abramson, Vandana G. , Agnese, Doreen Marie , Allison, Kimberly H. , Bailey, Janet E., Chew, Helen K. , Elias, Anthony , Giordano, Sharon H. , Goetz, Matthew P. , Jankowitz, Rachel C. , Javid, Sara H. , Leitch, A. Marilyn , Rosenberger, Laura H. , Rugo, Hope S. , Santa-Maria, Cesar Augusto , Schneider, Bryan P. , Soliman, Hatem, Speers, Corey , Wisinski, Kari B. , Yeung, Kay T. , Young, Jessica S. , Kumar, Rashmi

Mayo Clinic

Journal of the National Comprehensive Cancer Network | July 9, 2026 | Volume: 24 | Issue: 7 | Pages: No page available

10.6004/jnccn.2026.0033 | PMID 42425164 Get It

The NCCN Clinical Practice Guidelines for Breast Cancer include recommendations for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget’s disease, Phyllodes tumor, inflammatory breast cancer, and management of breast cancer during pregnancy. The panel convenes annually to update recommendations based on a review of recently published clinical trials. This selection from the NCCN Guidelines for Breast Cancer focuses on the recommendations for the management of recurrent or stage IV (M1) metastatic breast cancer. It summarizes the treatment strategies stratified by tumor biology, including hormone receptor status and HER2 expression, as well as clinical factors such as prior therapy and disease-free interval. Throughout all treatment lines, supportive care, quality of life preservation, toxicity minimization, and clinical trial participation are emphasized as integral components of patient care.
Consensus Guidelines for Staging and Surveillance Imaging in Cutaneous Squamous Cell Carcinoma
Kassamali, Bina , Schoenfeld, Jonathan D., Sethi, Rosh, Bakst, R H, Barker, C. A., Bradford, Carol R., Carr, David R., Chandra, Sunandana , Connolly, Karen L., Demer, Addison M. , Doonan, Bently, Emerick, Kevin, Friedman, Ben J. , Gali, Linna L., Galloway, Thomas J., Geiger, Jessica L., Kohen, Laurie, Koyfman, Shlomo, Kumar, Shweta Sharat, Learned, Kim O. , Leitenberger, Justin J., Lilley, Elizabeth J. , Lukens, John N. , Medina, Theresa , Mitra, Devarati , Ozog, David, Pashtan, Itai, Pham, Nancy , Powers, Molly, Srivastava, Divya, Taylor, Charlotte S., Witek, Matthew E. , Wysong, Ashley, Zander, David, Silk, Ann W., Jambusaria-Pahlajani, Anokhi, Ruiz, Emily S., Chen, Michelle , Kumar, Shweta S. , Schoenfeld, Jonathan D. , Barker, Christopher A. , Bhatt, Alok A. , Bradford, Carol R. , Bunch, Paul M. , Carr, David R., Carucci, John A. , Chen, Michelle , Connolly, Karen , Doonan, Bently P. , Emerick, Kevin S. , Friedman, Ben J. , Galloway, Thomas J. , Guenette, Jeffrey P. , Kelly, Hillary R. , Khushalani, Nikhil I. , Kohen, Laurie Linden, Leitenberger, Justin J. , Medina, Theresa M. , Pashtan, Itai , Patel, Vishal Anil , Srivastava, Divya , Swiecicki, Paul Loren , Wysong, Ashley, Silk, Ann Willman , Jambusaria‐Pahlajani, Anokhi , Ruiz, Emily S.

Mayo Clinic

JAMA Dermatology | July 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamadermatol.2026.2163 | PMID 42418212 Get It

Importance There is no consensus on staging and surveillance imaging for cutaneous squamous cell carcinoma (CSCC). Although imaging has been shown to affect management, broad recommendations from the National Comprehensive Cancer Network have led to variability in clinical practice. Objective To develop multidisciplinary consensus recommendations on the use of staging and surveillance imaging of localized CSCC. Evidence Review A multidisciplinary expert panel across academic and clinical practice settings convened a Delphi consensus, with 3 iterative survey rounds from January to June 2025. Data were analyzed from February 2025 to January 2026. Eligibility defined by at least 1 to 2 CSCC publications during the previous 5 years, involvement in a relevant clinical trial, experience treating at least 3 patients monthly with CSCC, and/or 5 years or longer of clinical practice. Fifty-four experts were invited and 45 (83%) completed all 3 rounds and were included in the final analysis. Structured Delphi surveys evaluated clinical scenarios, imaging modalities, and surveillance strategies for CSCC. Consensus and near-consensus recommendations were generated, defined as 80% or greater and 70% to 79% agreement, respectively. Findings The 45 participants (21 female individuals [47%] and 24 male individuals [53%]; 14 Asian individuals [31%], 1 multiracial individual [2%], and 30 White individuals [67%]) consisted of dermatology (15 [33%]), medical oncology (7 [16%]), radiation oncology (9 [20%]), radiology (9 [20%]), surgery (3 [7%]), and otolaryngology specialists (2 [4%]). The Delphi panel recommended staging and surveillance for CSCCs with at least a 15% risk of metastasis. Consensus or near consensus was reached to recommend staging and surveillance imaging for tumors with a concern for metastasis, bone invasion, invasion beyond subcutaneous fat, large-caliber nerve invasion, or a diameter of 4 cm or larger or the combination of tumors with poorly differentiated histology and any of the following: diameter of 2 cm or larger, lymphovascular invasion and subcutaneous fat invasion, or lymphovascular invasion and small-caliber perineural invasion. Computed tomography imaging was the preferred modality for nodal staging (38 [84%]) and surveillance (35 [78%]). For surveillance duration, consensus was reached to provide imaging for at least 2 years, and near consensus was reached for at least 3 years. Conclusions and Relevance This study provides an expert consensus–based framework to standardize imaging in localized CSCC that may inform future guidelines.
Evaluating the role of youth-onset diabetes mellitus in the context of food insecurity and preventive care: a repeated cross-sectional study using propensity score weighted machine learning analysis
Lee, Yu-Sheng , Stetson, Raymond C. , Hollender, Heaven, Sprong, Matthew E. , Huang, Xueli, Kumar, Karan, Joshi, Urja Nimitkumar, Lee, Yu-Sheng , Hollender, Heaven

Mayo Clinic

BMJ Paediatrics Open | July 8, 2026 | Volume: 10 | Issue: 1 | Pages: e003792

10.1136/bmjpo-2025-003792 | PMID 42419911 Get It

Background Youth-onset diabetes mellitus (DM) is an increasing public health concern, especially among adolescents facing socioeconomic challenges. Food insecurity (FI), a key social determinant of health, has been linked to adverse metabolic outcomes, but its association with youth-onset DM and the role of preventive care remain unclear. Methods Using repeated cross-sectional data from the National Survey of Children’s Health (2016–2021), we examined the association between FI status (food secure, mild FI and moderate-to-severe FI) and youth-onset DM among adolescents aged 10–17 years. We also evaluated whether usual preventive care modified this association. Propensity score weighting (PSW) was used to reduce the imbalance of measured confounders across FI groups. These weights were applied in the least absolute shrinkage and selection operator logistic regression for variable selection and in the final multivariable logistic regression models. Results In the PSW analysis of 66 560 adolescents, 432 had youth-onset DM. Moderate-to-severe FI was associated with higher odds of DM than food-secure adolescents (OR 1.55, 95% CI 1.35 to 1.77; p<0.0001), whereas mild FI was not associated with youth-onset DM. Among adolescents with preventive care visits, both mild FI (OR 1.19, 95% CI 1.04 to 1.37; p=0.0126) and moderate-to-severe FI (OR 1.67, 95% CI 1.46 to 1.92; p<0.0001) were associated with higher odds of DM. Among those without preventive care visits, FI was associated with lower odds of having a reported DM diagnosis, especially in the moderate-to-severe FI group (OR 0.11, 95% CI 0.03 to 0.35; p=0.0002). Conclusions Moderate-to-severe FI was associated with youth-onset DM, and this relationship varied by access to preventive care. Adolescents with FI who lack regular preventive care may have fewer opportunities for DM diagnosis. Public health strategies should integrate FI screening, equitable access to preventive services and culturally responsive approaches to chronic disease prevention.
Disrupted functional connectivity during stroke recovery revealed via bedside optical neuroimaging
Fogarty, Morgan , Ferradal, Silvina L., Dhar, Rajat, Kumar, Gyanendra, Lee, Jin‐Moo , Eggebrecht, Adam T. , Bergonzi, Karla M , Fogarty, Morgan , Lee, Jin-Moo , Eggebrecht, Adam T , Bergonzi, Karla M. , Burke, Broc A., Sherafati, Arefeh , Burns‐Yocum, Tracy M. , Ferradal, Silvina L. , Palanca, Ben Julian A. , Dhar, Rajat , Culver, Joseph P.

Mayo Clinic

Neurophotonics | July 8, 2026 | Volume: 13 | Issue: 03 | Pages: No page available

10.1117/1.nph.13.3.035002 | PMID 42422725 Get It

SignificanceCurrent clinical care following ischemic stroke provides intermittent assessments, potentially missing early detection of neurological deterioration. Optical imaging offers the potential for a continuous, portable alternative to the current combination of physical exams and radiological imaging. However, optical imaging technology has lacked the crucial combination of portability, resolution, and coverage required to assess spatially distributed brain function.AimHere, we present a proof-of-principle study that applies recent advancements in portable high-density diffuse optical tomography (HD-DOT) instrumentation and a functional connectivity analysis strategy to assess spatially distributed brain connectivity. Point-of-care brain health assessments with these tools may inform clinical care and our understanding of brain injury throughout acute stages of stroke recovery.ApproachWe measured spatially distributed cortical oxygenation with HD-DOT within the intensive care unit in N=13 patients with ischemic stroke within the first 72-h since last known normal. To assess brain function integrity, we developed a Similarity metric of functional connectivity (FC) through comparisons to FC in a healthy young adult population. To assess the sensitivity of this FC Similarity metric to disruptions caused by stroke, we compared these data with FC Similarity assessed in an older healthy cohort. We administered the NIH Stroke Scale to stroke patients to evaluate the potential of the FC Similarity metric to inform the severity of functional disruptions.ResultsThe FC Similarity metric applied to HD-DOT data in both acute stroke patients and healthy older controls exhibited a significant sensitivity to the presence of a stroke (Cohen’s d=1.5, p=1.2×10−3) and a significant relationship with the degree of neurological disruption as measured by the NIH Stroke Scale (R2=0.69, p=4.7×10−4).ConclusionsWe present a proof-of-principle for HD-DOT and the FC Similarity metric for assessing brain function during the acute stage of ischemic stroke recovery at the point-of-care.
Proteomic markers enhance mortality prediction in heart failure
Meyre, Pascal , Li, Y, Rocha, Guilherme L. da, Chong, M, Roy, Ambuj , Karaye, Kamilu M. , Störk, Stefan, Mielniczuk, L , Wittlinger, Thomas , Abdullakutty, Jabir, Nunez, J, Jathappa, Narendra, McCready, Tara, Grinvalds, Alex, Gerstein, Hertzel, Joseph, Philip , Meyre, Pascal B , Roy, Ambuj , Mielniczuk, Lisa, Lanas, Fernando , Yusuf, Salim , Paré, Guillaume , Li, Yanran, Shemesh, Elad , Störk, Stefan , Sharma, Sanjib Kumar , Mohan, Bishav , Laņas, Fernando , Celik, Ahmet , Abdullakutty, Jabir, Ogah, Okechukwu S. , McCready, Tara , Grinvalds, Alex, Gerstein, Hertzel C. , Leong, Darryl P. , Yusuf, Salim , Paré, Guillaume

Mayo Clinic

European Heart Journal | July 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/eurheartj/ehag525 | PMID 42414001 Get It

Abstract Background and Aims Clinical models incompletely capture the molecular pathways driving heart failure (HF) progression. This study evaluated whether molecular risk stratification provides incremental prognostic information beyond established clinical predictors in patients with HF. Methods A total of 2432 patients from the Global Congestive Heart Failure (G-CHF) registry with available genotyping, DNA methylation, and proteomic profiling were analysed. Three molecular scores were assessed: a composite cardiovascular polygenic risk score (PRS) from DNA sequence polymorphisms, a methylation risk score (MRS) derived from epigenome-wide associations, and a 23-protein-based score (ProteomicDeath23). Each score was tested individually and in combination with the clinical Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) risk score and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels for mortality prediction. Validation was performed in an HF subset of the UK Biobank (UKB). Results Over a median follow-up of 3.0 years in G-CHF, 523 patients died from any cause (7.64 per 100 person-years [PY]). In multivariable analyses, ProteomicDeath23 was the strongest independent predictor of all-cause mortality (hazard ratio [HR] per 1 standard deviation, 2.23), outperforming NT-proBNP (HR 2.00), MRSMortality (HR 1.66), PRSmetaCVD (HR 1.10), and the MAGGIC score (HR 1.70). A model combining ProteomicDeath23 with MAGGIC and NT-proBNP achieved the highest discrimination for mortality (C-index, 0.77). Addition of MRSMortality to this proteomic-clinical model resulted in only small improvements in discrimination (ΔC-index, +0.004, P = .0039), while the PRSmetaCVD provided no incremental benefit. Among patients with low NT-proBNP/MAGGIC score, mortality rates increased from 1.71 to 8.12 per 100 PY across ProteomicDeath23 tertiles. Consistent results were observed in the UKB-HF validation cohort. Conclusion A proteomic score was the strongest molecular predictor of mortality in HF. Integrating proteomic signatures with clinical risk factors significantly improved risk prediction.
Acetazolamide‐Responsive Exertion‐Triggered Episodic Ataxia in DHDDS ‐Related Congenital Disorder of Glycosylation
Muniswamy, Jai Kumar Rajavoor , Selvido, Liam , Zele, Elise Van, Satyanarayana, Raj, Morava, Eva, Muthusamy, Karthik , Van Zele, Elise, Muthusamy, Karthik , Rajavoor Muniswamy, Jai Kumar , Morava, Éva

Mayo Clinic

Movement Disorders Clinical Practice | July 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/mdc3.70723 | PMID 42394283 Get It